# Successfully Measuring Healthcare Analytics & Process Improvement (HAPI)

Becker's Health IT + Revenue Cycle Conference Chicago, IL September 2018

Brad Brimhall, MD, MPH





HAPI

Healthcare Healthcare Analytics & Analytics, **P**rediction, Process mprovement Process mprovement & Estimating Risk

## **Early Appeal for Healthcare Analytics**

"I am fain to sum up with an urgent appeal for adopting this or some uniform system of publishing the statistical records of hospitals. If they could be obtained . . . They would show subscribers how their money was being spent, what amount of good was really being done with it, or whether the money was doing mischief rather than good."


Florence Nightingale "Some Notes on Hospitals" (1863)



## **Healthcare Value**

**1. Improve patient outcomes** 


2. Improve patient satisfaction



**3. Decrease costs** 

4. Simplify operational tasks/improve efficiency


#### **Laboratory Analytics Value Flow**



## Examples

Projects

#### Laboratory Data Warehouse



## **LAN Laboratory Portal**

Eile       Edit       Yiew       Favorites       Tools       Help            ← Back	inks »
Address 🕘 http://medms2/clinlab/	.inks »
	.inks »
University of Colorado Hospital Clinical Laboratory	
<u>ABCDEFGHIJKLMNOPQRSTUVWXYZ</u>	
Quick Test Lookup     Tests with CPT     Tests with SIM     Fax Nbr for Client     Lookup Fax Number       Submit     Submit     Submit     Submit	
ClinLab Home Other Reports	
• Web Links	
Employee Resources Caution: Data for this system is 24 hours behind Cerner	
E Reports	- 11
Client Services      TAT     List Samples for Test	
TAT List Samples for Test     Workload	
Blood Bank Start Date End Date Mnemonic	
···ICD-9	
Instrument Compariso	-
List Low Samples for Test	
Micro	
Submit         Start Date         Mnemonic         Cutoff	
Post Analytical Storag	-
Management List High Samples for Test	
Cerner - Web	
AllScripts Submit Start Date End Date Cutoff	
Document Imaging     Determined and and and and and and and and and an	_
- Engineering Service Rem	-
Forms	
Submit Start Date End Date Mnemonic Low High	
Close all	
🕘 Done	

#### Data Warehouse: Project ROI (Actual)

#### Realized Cost Savings (2005)\*

Annual savings Pct of total laboratory costs \$746,200 4.5%

# Profitability (actual figures 1998-2005)\* Payback period (actual) 1.47 y NPV \$2,968,639 MIRR 59.4%


#### **\*\*Still being used!**

\*Brimhall BB, Hall TE, Walczak S. *AMIA Annu Symp Proc* 2006:865 \*\* Boyer PJ, Brimhall BB, Williamson C, et al. J Pathol Inform 2014;5:S14


#### **Duplicate Laboratory Testing**

Same test Same patient Within 4-hour time window

#### **Duplicate Test Orders**



#### **Canceled Tests**




Month

### **Duplicate Testing Alerts**


#### **Annualized Totals**

Test	Total	Canceled	Percent Canceled	Variable Cost	Total
ВМР	12,706	5,204	41.0%	\$40,730	\$63,875
СВС	6,728	2,296	34.1%	\$9,574	\$17,668
CBC W/ DIFF	5,880	2,387	40.6%	\$9,954	\$18,368
MG	3,591	1,914	53.3%	\$6,393	\$16,346
PO4	5,100	2,718	53.3%	\$5,925	\$15,166
TOTAL	34,005	14,519	42.7%	\$72,576	\$131,423


## **Rapid Bacterial Identification**




#### **Current Methods**




#### Fast, inexpensive, limited





#### Slow, expensive, accurate





# **Initial Financial Analysis**

Sec. 1	Year						
Item	Investment	1	2	3	4	5	Total
Cost of instrument	(\$312,387)	\$0	\$0	\$0	\$0	\$0	(\$312,387)
Service contract	\$0	\$0	(\$19 <i>,</i> 178)	(\$19,178)	(\$19,178)	(\$19,178)	(\$76,710)
Cost savings from reagents	\$0	\$33,408	\$33 <i>,</i> 408	\$33 <i>,</i> 408	\$33,408	\$33 <i>,</i> 408	\$167,040
Sum of cash flows	(\$312,387)	\$33,408	\$14,230	\$14,230	\$14,230	\$14,230	(\$222,058)
PV cash flows	(\$312,387)	\$33,408	\$13,553	\$12,907	\$12,293	\$11,707	(\$228,519)

Payback Period	
Payback period (years)	20.60
Payback period (months)	247.25
Payback period (weeks)	1,071.43

#### Modified Internal Rate of Return

Discount rate	5%
Reinvestment rate	2%
MIRR	-22.34%

#### Net Present Value

Discount rate Project NPV

5%	6
(\$228,519	)

## Literature: Diagnostic Efficiency

#### **Reduced Time to Bacterial Identification**

Mean reduction = "34.3 hours" Lagace-Wiens, P.R.S., Adam, H.J., Karlowski, J.A., et al. (2012). *J Clin Microbiol* 50:3324-3328. [University of Manitoba, Winnipeg, MB]

Mean reduction = "1.45 days" (34.8 hours) Tan, K.E., Ellis, B., Lee, R., et al. (2012). *J Clin Microbiol* 50:3301-3308. [Johns Hopkins University, Baltimore, MD]

Mean reduction = "28.8 hours" Vlek, A.L.M., Bonten, M.J.M., & Boel, C.H.E. (2012). *PLoS ONE* 7:e32589. [Univ. Medical Center, Utrecht, NL]

#### **Implications for Patient Care**

Reduced time to appropriate therapy: 28.8% of patients (treating physician), 44.6% of patients (stewardship team) Tamma, P.D., Tan, K., Nussenblatt, V.R., et al. (2013). *Infect Control Hosp Epidemiol* 34:990-995. [Johns Hopkins University, Baltimore, MD]

Increase in proportion of patients receiving appropriate treatment at 24 hours: 11.3% Vlek, A.L.M., Bonten, M.J.M., & Boel, C.H.E. (2012). *PLoS ONE* 7:e32589. [Univ. Medical Center, Utrecht, NL]

Percent with modification of empirical therapy: **35.1%** Clerc, O., Prod'hom, G., Vogne, C., et al. (2013). *Clin Infect Dis* 56:1101-1107. [Univ. of Lausanne, Lausanne, CH]

## **Diagnostic Cost Accounting Data**

Queried Diagnostic Groups					
MSDRG Code	Interpretation				
870	Septicemia with mechanical ventilation				
871	871 Septicemia without mechanical ventilation with major complications/comorbidities				
872 Septicemia without mechanical ventilation without major complications/comorbidities					

Operational Inputs					
Patients	755				
Patients with LOS > 2d	710				
Mean LOS (d)	7.49				

Expenses	Total	Per Admission	Per Day
Mean Fixed Costs	\$2,958,004	\$4,166	\$556
Mean Variable Costs	\$7,826,845	\$11,024	\$1,472
Mean Total Costs	\$10,784,849	\$15,190	\$2,028

# **New Financial Analysis**

	Year						
Item	Investment	1	2	3	4	5	٦
Cost of instrument	(\$312,387)	\$0	\$0	\$0	\$0	\$0	(
Service contract	\$0	\$0	(\$19,178)	(\$19,178)	(\$19,178)	(\$19,178)	
Cost savings from reagents	\$0	\$33,408	\$33 <i>,</i> 408	\$33 <i>,</i> 408	\$33,408	\$33 <i>,</i> 408	
Cost savings from earlier discharge	\$0	\$1,253,967	\$1,253,967	\$1,253,967	\$1,253,967	\$1,253,967	Ş
Sum of cash flows	(\$312,387)	\$1,287,375	\$1,268,198	\$1,268,198	\$1,268,198	\$1,268,198	\$

#### **Payback Period**

Payback period (years)	
Payback period (months)	
Payback period (weeks)	

#### Net Present Value

Discount rate
Project NPV

0.24
 2.91
12.62


5%

\$5,471,954

#### **Modified Internal Rate of Return**

Discount rate	5%
Reinvestment rate	2%
MIRR	80.79%

## **Sensitivity Analysis**



#### **Hospital Blood Donor Center**



## **One View of Donor Center**

#### **Revenue and Expense view of operation**

- Revenue: billed CPT codes for therapeutic phlebotomies
- Expenses greatly exceed revenue resulting in substantial net loss
- Therefore the operation should be closed

Acme Web Pros Plus						
For the month ended .	June 30, 2017	MAY 2017	APR 2017	MAR 2017	FEB 2017	JAN 2017
Income						
Branding & Design	200.00	400.00		3,250.00		
Consulting Fees	300.00					
Digital Marketing	500.00	•		785.00	1,200.00	1,200.00
Sales				285.00		
Web Design Income	1,100.00	800.00		1,950.00		
Total Income	2,100.00	1,200.00	•	6,270.00	1,200.00	1,200.00
Gross Profit	2,100.00	1,200.00		6,270.00	1,200.00	1,200.00
Operating Expenses						
Dues and Subscription Fees	775.00	75.00	600.00	200.00	300.00	100.00
Other Expense	•	-	1,000.00	-	-	
Parking fees		100.00	-			-
Postage & Shipping Fees	•	•	23.95			
Travel Expenses	870.00	500.00			-	
Web Hosting		400.00	400.00	40.98	(32.92)	32.92
Total Operating Expenses	1,645.00	1,075.00	2,023.95	240.98	267.08	132.92
Operating Income	455.00	125.00	(2,023.95)	6,029.02	932.92	1,067.08
Net Income	455.00	125.00	(2.023.95)	6.029.02	932.92	1,067.08


# **Contribution Analysis (TTM)**

d					
	and the second se	Whole Blood	Platelet	Total	Percent
5	Outside Cost	\$1,579,425	\$579,960	\$2,159,385	100.0%
2	Less Consumables	\$218,632	\$199,769	\$418,401	19.4%
	Less Testing	\$312,380	\$37,246	\$349,626	16.2%
	Less Supplies	\$8,020	\$956	\$8,976	0.4%
ŝ	Less Incentives	\$87,557	\$10,440	\$97,997	4.5%
2	Contribution to Labor	\$952 <i>,</i> 835	\$331,549	\$1,284,384	59.5%
	Less Labor	\$352,642	\$62,231	\$414,873	19.2%
	Less Recruiting	\$92,604	\$16,342	\$108,946	5.0%
	Contribution to Local Fx	\$507,589	\$252,976	\$760,564	35.2%
3	Regulatory Costs	\$3,698	\$653	\$4,351	0.2%
	Common Supplies	\$5,863	\$1,035	\$6,898	0.3%
	Equipment Costs	\$229,311	\$40,466	\$269,777	12.5%
2	Contribution to Overhead	\$268,716	\$210,822	\$479,538	22.2%


#### **Seeing the Donor Center in New Light**




## **Blood Product Collections**




#### **Donor Center Net Savings**




#### **Heparin-Induced Thrombocytopenia**



#### **Expensive Anticoagulants**



#### **Test Result Distribution**




#### **HIT 4Ts Pre-Test Probability Score**

Category	2 Points	1 Point	0 Points
Thrombocytopenia	Plt fall >50% AND plt nadir ≥20K/uL	Plt fall 30%-50% AND plt nadir 10K-20K/uL	Plt fall <30% AND plt nadir ≤10K/uL
Timing of platelet count fall	Clear onset fall 5- 10 d OR plt fall ≤1 day IF heparin exposure within previous 30d	Consistent with fall 5- 10d but not clear (e.g., missing data) OR onset after 10d OR fall ≤1d (previous heparin exposure prior 30- 100d)	Platelet fall <5d without recent heparin exposure
Thrombosis or other sequelae	New thrombosis (confirmed) OR skin necrosis at heparin injection sites OR acute systemic reaction after heparin bolus	Progressive or recurrent thrombosis OR non-necrotizing skin lesions OR suspected thrombosis (not proven)	None
Other causes of thrombocytopenia	None apparent	Possible	Definite

Adapted from: Cuker A. Semin Thromb Hemost 2014;40:106-114

#### **Bayesian Analysis of HIT Testing**



From: Cuker A. Semin Thromb Hemost 2014;40:106-114.


#### **EMR Alert with Questions**

🔡 Antiplat	elet Antibody Order Form -	UHSTEST, BECK						
UHSTEST	BECK						16590748 / 100071648	7y1m (Aug-07-2007) Male 🕜
01 Allergi	es: ABREVA, TREE NUTS, LATEX							
Order:	Heparin Dependent Platelet A	B IGG					Order ID: 001 NYMSRE	3
Requested By	Arora, Komal					Template Name:		
Messages:								
								(27)
Request Date Sep-25-2014	1					Request Time Routine		N
						Specimen Source		24 1
Specimen Ty Blood	pe					Specimen Source		P
Attending Phy	rsician					Indication		•
Olson, John, I					Ş	Thrombosis; Heparin related		Ş
Degree of Pla	telet Fall							
More than 50	% fall in platelet count from baseline	э.						<b>₽</b>
Timing of Pla								
	let fall between 5-14 days after exp	posure to Heparin.						b .
Thrombosis								101
	sis; Acute systemic reaction following	ng thrombosis						<u>عا</u>
	of Thrombocytopenia							N
Conditional C	ogy for drop in platelet count.			Sunrise Clin	ical Manager			لو ا
Max # of a								
	¥			—		n this order form, the risk of HIT in this patient stopped and anticoagulation with a Direct		<ul> <li>Clear</li> </ul>
					Thrombin Inhibitor started.	Testing for Heparin Platelet Antibodies is		
Special Instru	ictions				indicated.			
						ок		
				<u> </u>				
								-
Ordering Pro	vider Information							
	e = Arora, Komal / UHS Number	= 24388						
LAB Collectio	n Info							
RED TOP TU	BE 7mL (CERNER Code: 160000	10)						
Ordering Visi	t Information							
	Status: ADM Ordering Visit Numb	er: 100071648						
LAB Indicatio	n					1		
Evidence Ava	ilable							
					<b>F</b>	1		
Repeat	View Document							Add Close
🛃 start		Play Script	Play Script	C Electronic Requisi	tion 🛞 Allscripts Gatev	vay   🧑 Microsoft PowerPoint		<
					· · · · · · · · · · · · · · · · · · ·			

# **Changes Over Time**

	2007	2011	<b>Change</b>
HIT Tests	224	67	-157
Test Variable Cost	\$26,320	\$7,872	(\$18,448)
	<b>1 1</b>	<b>T</b> · <b>J</b> - · -	() = = ) = = = )
Drug Variable Cost	\$313 964	\$93,909	(\$220,055)
Diag variable cost	7313,30 <del>4</del>	,JUJ	(7220,033)

#### **Post-Hospitalization Care**



#### **"Ideation" Room**




Patient status	Resoult of contract	Since last EC/Adm
Lo Artive Lo Disensited Lo Disensited Lo	Lə Yes Lə LM Lə Band <sup>#</sup> Lə Natromeilabra	Lə Ak Lə Ec Lə Admission
Veeds (HARRY) Frie appli- Med reft1	Resonancedas La Transportation La Transportation	Best hime to contract
fW needs Case mangen ant Medical 5 Resorce from page-	Lo Facil Lo Utiliz Lo Engloyney Lo Sitely Lo Education Lo Day care	Perferred carbot
PCOmmunity reserves	Lo Subdur le Atorise	Lo Emil
Meas latt fur bob Special new bx 3 0 0	sie	

# **Total Hospitalizations**





12,000	
10.000	Other
10,000	
8,000	
6,000	
4,000	
2,000	
0	]

#### **Average Hospital LOS (days)**




#### **Average Hospital Variable Cost**







#### **Average Annual Variable Cost Savings**




## **Hospital Readmission Rates (30-days)**




#### **Integrated** Data



#### **Healthcare Data Stores**



#### **Healthcare Analytics & Process Improvement**





# Questions